Products
Rh
Rho
TM
[ roh ]
an opportunistic screening system for low bone mineral density
Ph
Physis
TM
[ fahy-sis ]
a smart atlas for pediatric bone age assessment
Company
Partners
News
Contact Us
Rh
Rho
TM
132,590
lives impacted by Rho
Rho utilizes routinely captured x-rays to opportunistically identify patients at risk of osteoporosis.
FAQ →
Request a Demo →
Get Started →
Licensed by
Health Canada
FDA De Novo
Marketing Authorization
This product is protected by U.S. Patent No. US11737704B2. All rights reserved.
80% of people aged 50+ undergo an x-ray.
Rho
TM
can analyze these x-rays for low bone mineral density.
Radiologist receives report for patients at risk.
Findings and recommendations are shared with the provider.
Provider develops personalized care plan with the patient.
Increased reimbursable services for at risk patients.
Clinical Risk Assessment
Fall Prevention
Lifestyle Modification
DXA Screening
Osteoporosis Care Reimagined.
Impacting care through AI-driven opportunistic screening.
Only
1 in 4
eligible women are currently screened for osteoporosis.
Up-to
50%
of men are never screened for osteoporosis.
Rho
TM
can utilize
80%
of imaging data captured during routine care.
Number of individuals with low BMD:
42 million
potential lives impacted.
Benefits to Our Customers
Finally, AI designed to improve outcomes for the patients you serve delivered through a value-based care model.
Leverage Existing Data
Increase Screening Rates
Increase Revenue
Maximize DXA Capacity
Cloud or On-Premise
PACS Integration
Request a Demo Today
Request a Demo →
